跳至主要内容
临床试验/IRCT20130313012810N7
IRCT20130313012810N7已完成未知

Comparative bioequivalence study of the Amiodarone 200-mg Tablets manufactured by Behestan Pharmaceutical Company

Behestan Daru Co0 个研究点目标入组 24 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
Male

入选标准

  • The weight range of participating candidates must be between 60-100 kg
  • All candidates must be non-smokers
  • The candidates must be healthy in terms of physical examination, ECG and the following laboratory tests: hemoglobin, hematocrit, red and white blood count, MCV ( mean body mass), MCH (mean body hemoglobin), routine urinalysis, total cholesterol, triglycerides, total proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), amino aspartate transferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose
  • Volunteers who agreed to the informed consent form

排除标准

  • History of sensitivity or idiosyncrasy to amiodarone or any of the inactive components of the formulation.
  • Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg.
  • Taking any medication within 2 weeks before receiving the medication.

研究者

发起方
Behestan Daru Co

相似试验